Digest Network Come funziona
Network
/
Società
Lo
Non verificato

Longboard Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

16 comunicati stampa

Guarda tutti i comunicati
12/11/2024
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)
Fonte
Longboard Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
07/11/2024
Web e Social Network
Telefonia e Varie
Mercato azionario
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Fonte
Longboard Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
14/10/2024
Multimedialità
Web e Social Network
Finanza
Telefonia e Varie
Mercato azionario
Salute
Igiene alimentare
Medicina - Varie
Farmaceutica
Biotecnologia
Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline
Fonte
Longboard Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
04/10/2024
Mercato azionario
Finanza
Salute
Scienza
Farmaceutica
Biotecnologia
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Fonte
Longboard Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
26/09/2024
Industria
Scienza
Igiene alimentare
Comunicazione
Medicina - Varie
Biotecnologia
Sanità
Farmaceutica
Salute
Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome
Fonte
Longboard Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
19/09/2024
Industria
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Longboard Pharmaceuticals Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Bexicaserin (LP352) in Dravet Syndrome
Fonte
Longboard Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
08/09/2024
Eventi
Industria
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
Longboard Pharmaceuticals Announces Positive Interim Analysis Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)
Fonte
Longboard Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
06/09/2024
Mercato azionario
Finanza
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Fonte
Longboard Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
28/08/2024
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Web e Social Network
Longboard Pharmaceuticals to Participate in Four Upcoming Investor Conferences in September
Fonte
Longboard Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
26/08/2024
Scienza
Finanza
Medicina - Varie
Associazioni/Professionisti
Sanità
Biotecnologia
Farmaceutica
Salute
Eventi
Longboard Pharmaceuticals to Present Late-Breaking and Encore Data at the 15th European Epilepsy Congress
Fonte
Longboard Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0